Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Buccal cell cytokeratin 14 identifies mild cognitive impairment and alzheimer's disease in the aibl study of aging
Author: Leifert, W.
Tuli, J.
Francois, M.
Nguyen, T.
Rembach, A.
Rumble, R.
Rainey-Smith, S.
Martins, R.
Fenech, M.
Citation: Current Alzheimer Research, 2015; 12(3):233-241
Publisher: Bentham Science Publishers
Issue Date: 2015
ISSN: 1875-5828
Statement of
Wayne R. Leifert, Jannatul Ferdoush Tuli, Maxime Francois, Tori Nguyen, Alan Rembach, Rebecca L. Rumble, Stephanie Rainey-Smith, Ralph Martins, Michael F. Fenech, The Australian Imaging and Biomarkers and Lifestyle Study Research Group
Abstract: Previous studies have suggested that mild cognitive impairment (MCI) may be reflective of the early stages of neurodegenerative disorders such as Alzheimer's disease (AD). The hypothesis was that cytokeratin (CK) 14 expression can be used as a biomarker in isolated buccal mucosa to identify individuals with MCI or AD from the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging. Visual assessment of buccal cell CK14 expression was carried out using immunofluorescence techniques. The frequency of basal buccal cells expressing CK14 was significantly lower in the MCI (P=0.0002) and AD (P<0.05) groups compared with the control group. Receiver-operating characteristic (ROC) curves were carried out for CK14 expression and yielded an area under the curve (AUC) of 0.899 for the MCI (P<0.0001) group and 0.772 for the AD (P=0.004) group. When the CK14 expression data were combined with plasma homocysteine concentration, the AUC was further improved to 0.932 and 0.788 for the MCI (P=0.0001) and AD (P=0.004) groups, respectively. APOE ε4 carriers in the control group had 21% lower CK14 expression compared with control non APOE ε4 carriers, however this difference was not statistically significant. The changes in the buccal cell CK14 expression observed in this pilot study could prove useful as a potential biomarker in identifying individuals with an increased risk of developing MCI and eventually AD. These promising results need to be replicated in a larger subset of the AIBL cohort and in cohorts of other neurodegenerative disorders to determine changes specific to AD.
Keywords: AIBL; Alzheimer’s disease; Buccal cells; cytokeratin; homocysteine; immunofluorescence
Rights: © 2016 Bentham Science Publishers. This site is owned and operated by Bentham Science Publishers. You may download sample copies on a single computer for personal or non-commercial temporary use, providing you take into account the copyright and any other trademark notices. No content however, may be copied, reproduced, distributed, republished or posted. If you download content from this site, the content remains licensed with Bentham Science Publishers.
DOI: 10.2174/1567205012666150302154650
Appears in Collections:Aurora harvest 7
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.